Impact of hematologic toxicities during concurrent chemoradiation for cervical cancer
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Objective: To evaluate the prognostic significance of hematological toxicities during cervical cancer treatment. Methods: Patients treated for cervical carcinoma with definitive chemoradiation were identified. Toxicities were assessed during weeks 1 to 6 of concurrent external beam radiation and chemotherapy. Outcomes were analyzed using Cox regression analysis. Results: One hundred twenty-one patients with Federation of Gynecology and Obstetrics stage I-III disease were eligible for analysis. Median age at diagnosis was 45 years (interquartile range, 40-52) with median follow-up time of 34 months (95% confidence interval, 30.8-37.2). All patients experienced some grade of hematologic toxicity. The most common grade 3+ toxicities were low absolute lymphocyte count (n=115, 95%), low white blood cell count (n=21, 17%), and anemia (n=11, 9%). The most common grade 4 toxicity was lymphopenia, experienced by 36% of patients (n=44). Grade 4 lymphopenia was associated with reduced overall survival (hazard ratio [HR], 4.5; P=0.005), progression-free survival (HR, 3.4; P=0.001), and local control (HR, 4.1; P=0.047). Anemia grade 3, 4 was also associated with reduced overall survival (HR, 4.1; P=0.014). After controlling for disease and treatment variables, grade 4 lymphopenia remained significantly associated with reduced overall survival (HR, 9.85; P=0.007). The association with grade 4 lymphopenia only remained significant in women of Hispanic ethnicity. Conclusion: Severe lymphopenia was associated with reduced overall survival and progression-free survival in Hispanic women undergoing definitive chemoradiation for cervical cancer, but not associated with outcomes in non-Hispanic women.
Abstract
Objective: To evaluate the prognostic significance of hematological toxicities during cervical cancer treatment. Methods: Patients treated for cervical carcinoma with definitive chemoradiation were identified. Toxicities were assessed during weeks 1 to 6 of concurrent external beam radiation and chemotherapy. Outcomes were analyzed using Cox regression analysis. Results: One hundred twenty-one patients with Federation of Gynecology and Obstetrics stage I-III disease were eligible for analysis. Median age at diagnosis was 45 years (interquartile range, 40-52) with median follow-up time of 34 months (95% confidence interval, 30.8-37.2). All patients experienced some grade of hematologic toxicity. The most common grade 3+ toxicities were low absolute lymphocyte count (n=115, 95%), low white blood cell count (n=21, 17%), and anemia (n=11, 9%). The most common grade 4 toxicity was lymphopenia, experienced by 36% of patients (n=44). Grade 4 lymphopenia was associated with reduced overall survival (hazard ratio [HR], 4.5; P=0.005), progression-free survival (HR, 3.4; P=0.001), and local control (HR, 4.1; P=0.047). Anemia grade 3, 4 was also associated with reduced overall survival (HR, 4.1; P=0.014). After controlling for disease and treatment variables, grade 4 lymphopenia remained significantly associated with reduced overall survival (HR, 9.85; P=0.007). The association with grade 4 lymphopenia only remained significant in women of Hispanic ethnicity. Conclusion: Severe lymphopenia was associated with reduced overall survival and progression-free survival in Hispanic women undergoing definitive chemoradiation for cervical cancer, but not associated with outcomes in non-Hispanic women.
참고문헌 (40)
- Siegel RL, "Cancer statistics, 2019", CA Cancer J Clin, 69, pp.7~34 (2019)
- Marth C, "Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up", Ann Oncol, 28(suppl_4), pp.iv72~iv83 (2017)
- Yang T, "Predictors of hematologic toxicity during pelvic radiation therapy", Int J Radiat Oncol Biol Phys, 84(3), pp.S346~ (2012)
- Abu-Rustum NR, "Compliance with and acute hematologic toxic effects of chemoradiation in indigent women with cervical cancer", Gynecol Oncol, 81, pp.88~91 (2001)
- van Meir H, "Impact of(chemo)radiotherapy on immune cell composition and function in cervical cancer patients", Oncoimmunology, 6, pp.e1267095~ (2016)
- Schrijvers D, "Management of anemia in cancer patients:transfusions", Oncologist, 16(Suppl 3), pp.12~18 (2011)
- Berke G, "The binding and lysis of target cells by cytotoxic lymphocytes : molecular and cellular aspects", Annu Rev Immunol, 12, pp.735~773 (1994)
- Clemente CG, "Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma", Cancer, 77, pp.1303~1310 (1996)
- Sato E, "Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+", regulatory T cell ratio are associated with favorable prognosis in ovarian cancer, 2005, pp.102, 18538~18543
- Wu ES, "Lymphopenia and its association with survival in patients with locally advanced cervical cancer", Gynecol Oncol, 140, pp.76~82 (2016)
- Wild AT, "lymphocyte-sparing effect of stereotactic body radiation therapy in patients with unresectable pancreatic cancer", Int J Radiat Oncol Biol Phys, 94, pp.571~579 (2016)
- Cézé N, "Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy", Cancer Chemother Pharmacol, 68, pp.1305~1313 (2011)
- Kitayama J, "Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer", Radiat Oncol, 5, pp.47~ (2010)
- Schueneman AJ, "Low total lymphocyte count is associated with poor survival in patients with resected pancreatic adenocarcinoma receiving a GM-CSF secreting pancreatic tumor vaccine", Ann Surg Oncol, 20(Suppl 3), pp.S725~S730 (2013)
- Davuluri R, "lymphocyte nadir and esophageal cancer survival outcomes after chemoradiation therapy", Int J Radiat Oncol Biol Phys, 99, pp.128~135 (2017)
- Cho O, "Minimum absolute lymphocyte count during radiotherapy as a new prognostic factor for nasopharyngeal cancer", Head Neck, 38(Suppl 1), pp.E1061~E1067 (2016)
- Campian JL, "Treatmentrelated lymphopenia in patients with stage III non-smallcell lung cancer", Cancer Invest, 31, pp.183~188 (2013)
- Groopman JE, "Chemotherapy-induced anemia in adults : incidence and treatment", J Natl Cancer Inst, 91, pp.1616~1634 (1999)
- Knight K, "Prevalence and outcomes of anemia in cancer : a systematic review of the literature", Am J Med, 116(Suppl 7A), pp.11S~26S (2004)
- Dunst J, "Anemia in cervical cancers : impact on survival, patterns of relapse, and association with hypoxia and angiogenesis", Int J Radiat Oncol Biol Phys, 56, pp.778~787 (2003)
- 임소이, "An association between preoperative anemia and poor prognostic factors and decreased survival in early stage cervical cancer patients", Obstetrics & Gynecology Science, 57(06), pp.471~477 (2014), 대한산부인과학회[DOI]
- Rades D, "Challenges of anemia correction during radiotherapy and chemoradiation", Eur Med Oncol, 5, pp.35~38 (2012)
- Koulis TA, "Anemia, leukocytosis and thrombocytosis as prognostic factors in patients with cervical cancer treated with radical chemoradiotherapy : a retrospective cohort study", Clin Transl Radiat Oncol, 4, pp.51~56 (2017)
- Bishop AJ, "Relationship between low hemoglobin levels and outcomes after treatment with radiation or chemoradiation in patients with cervical cancer : has the impact of anemia been overstated?", Int J Radiat Oncol Biol Phys, 91, pp.196~205 (2015)
- Cho O, "Prognostic Value of Severe Lymphopenia During Pelvic Concurrent Chemoradiotherapy in Cervical Cancer", Anticancer Res, 36, pp.3541~3547 (2016)
- Bogani G, "Chemotherapy-related leukopenia as a biomarker predicting survival outcomes in locally advanced cervical cancer", Eur J Obstet Gynecol Reprod Biol, 208, pp.41~45 (2017)
- Ray-Coquard I, "Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas", Cancer Res, 69, pp.5383~5391 (2009)
- Fyles A, "The effect of treatment duration in the local control of cervix cancer", Radiother Oncol, 25, pp.273~279 (1992)
- Girinsky T, "Overall treatment time in advanced cervical carcinomas : a critical parameter in treatment outcome", Int J Radiat Oncol Biol Phys, 27, pp.1051~1056 (1993)
- Biewenga P, "Prognostic model for survival in patients with early stage cervical cancer", Cancer, 117, pp.768~776 (2011)
- Onal C, "The utility of pretreatment and posttreatment lymphopenia in cervical squamous cell carcinoma patients treated with definitive chemoradiotherapy", Int J Gynecol Cancer, 28, pp.1553~1559 (2018)
- Taguchi A, "Postradiotherapy persistent lymphopenia as a poor prognostic factor in patients with cervical cancer receiving radiotherapy : a single-center, retrospective study", Int J Clin Oncol, 25, pp.955~962 (2020)
- Azab B, "Average values and racial differences of neutrophil lymphocyte ratio among a nationally representative sample of United States subjects", PLoS One, 9, pp.e112361~ (2014)
- Warnke C, "Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia", Neurology, 83, pp.2153~2157 (2014)
- Borges TC, "High neutrophil to lymphocytes ratio is associated with sarcopenia risk in hospitalized cancer patients", Clin Nutr, 40, pp.202~206 (2021)
- Lee AY, "Hematologic nadirs during chemoradiation for anal cancer : temporal characterization and dosimetric predictors", Int J Radiat Oncol Biol Phys, 97, pp.306~312 (2017)
- Sini C, "Dose-volume effects for pelvic bone marrow in predicting hematological toxicity in prostate cancer radiotherapy with pelvic node irradiation", Radiother Oncol, 118, pp.79~84 (2016)
- Mell LK, "Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy", Int J Radiat Oncol Biol Phys, 66, pp.1356~1365 (2006)
- Dyer BA, "Role of immunotherapy in the management of locally advanced and recurrent", metastatic cervical cancer, 2019, pp.17, 91~97
- 오영택, "Risk factors for type-specific persistence of high-risk human papillomavirus and residual", recurrent cervical intraepithelial neoplasia after surgical treatment, 2020, pp.63(5), 631~642[DOI]